On October 11, 2024, Junshi Biosciences announced that its self-developed recombinant humanized anti-PCSK9 monoclonal antibody injection, Ongericimab (brand name: JUNSHID®). Has been approved by the National Medical Products Administration (NMPA) for the treatment of adult…
In the fight against severe and chronic auto-inflammatory diseases, Rilonacept Injection has emerged as a groundbreaking treatment, offering hope for patients battling debilitating conditions like Cryopyrin-Associated Periodic Syndromes (CAPS) and Systemic Juvenile Idiopathic Arthritis (SJIA).…
February 2025 – In a groundbreaking advancement in the treatment of platinum-resistant ovarian cancer, the investigational drug Mirvetuximab Soravtansine-Gynx has emerged as a potential game-changer. This novel therapy, developed by ImmunoGen, combines targeted monoclonal antibody…
February 2025 — In a significant advancement in the treatment of certain aggressive cancers, Sacituzumab Tirumotecan for Injection (brand name Trodelvy) has garnered attention for its innovative approach to fighting metastatic cancers. Approved by the…
February 2025 — In a significant breakthrough for cancer treatment, Loncastuximab Tesirine-lpyl (brand name Zynlonta) is rapidly gaining attention as a promising new option for patients with relapsed or refractory large B-cell lymphoma (LBCL). Recently…
In the rapidly advancing world of cancer treatment, Lunsumio(Mosunetuzumab) has emerged as a promising new therapy, offering hope to patients with certain types of B-cell non-Hodgkin lymphoma (NHL). This cutting-edge bispecific monoclonal antibody is poised…
In the ever-evolving landscape of oncology, a promising new drug, Zolbetuximab-Clzb for Injection, has made headlines as it advances through clinical trials and regulatory processes. This innovative monoclonal antibody is being developed as a potential…
In recent years, Vindesine Sulfate For Injection, as a chemotherapeutic drug, has demonstrated remarkable efficacy in the treatment of a variety of malignant tumors. As a paclitaxel, Vindesine plays an inhibitory role in tumor growth…
Selumetinib (INN) is sold under the trade name Koselugo and is a medication used to treat children aged 2 years and older with type I neurofibromatosis (NF-1). This drug provides a new treatment option for…
Developing Innovative Tablet Areas In the ever-evolving landscape of health and wellness, a new star has emerged on the horizon – Lentinus Edodes Mycelia Polysacharide Tablet. These innovative tablets are making waves in the supplement…
Nimustine hydrochloride for Injection is used to treat gliomas and other brain tumors. As a nitrogen mustard drug, nimustine effectively inhibits tumor growth by interfering with DNA synthesis in cancer cells, helping patients prolong survival…
Fludarabine phosphate for injection is used to treat chronic lymphocytic leukemia (CLL) and non Hodgkin lymphoma (NHL). As an anti metabolic drug, it effectively inhibits the proliferation of cancer cells by suppressing their DNA synthesis,…
